Dutasteride; Tamsulosin Hydrochloride Patent Expiration

Dutasteride; Tamsulosin Hydrochloride is used for treating benign prostatic hyperplasia and other androgen responsive or mediated conditions in mammals with Dutasteride. It was first introduced by Waylis Therapeutics Llc in its drug Jalyn on Jun 14, 2010. 5 different companies have introduced drugs containing Dutasteride; Tamsulosin Hydrochloride.


Dutasteride; Tamsulosin Hydrochloride Patents

Given below is the list of patents protecting Dutasteride; Tamsulosin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Jalyn US5565467 Androstenone derivative Nov 20, 2015

(Expired)

Waylis Therap
Jalyn US5846976 Androstenone derivative Sep 17, 2013

(Expired)

Waylis Therap
Jalyn US5998427 Androstenones Sep 17, 2013

(Expired)

Waylis Therap



Dutasteride; Tamsulosin Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Dutasteride; Tamsulosin Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Dutasteride; Tamsulosin Hydrochloride. The first generic version for Dutasteride; Tamsulosin Hydrochloride was by Endo Operations Ltd and was approved on Feb 26, 2014. And the latest generic version is by Aurobindo Pharma Ltd and was approved on Jul 18, 2024.

Given below is the list of companies who have filed for Dutasteride; Tamsulosin Hydrochloride generic, along with the locations of their manufacturing plants worldwide.


1. ACTAVIS LABS FL INC

Actavis Laboratories Fl Inc has filed for 1 generic for Dutasteride; Tamsulosin Hydrochloride. This 0.5mg;0.4mg version comes by the name DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.5MG; 0.4MG

capsule Discontinued ORAL N/A Nov 20, 2015





2. AUROBINDO PHARMA

Aurobindo Pharma Ltd has filed for 1 generic for Dutasteride; Tamsulosin Hydrochloride. This 0.5mg;0.4mg version comes by the name DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.5MG; 0.4MG

capsule Prescription ORAL AB Jul 18, 2024


Manufacturing Plant Locations
New

Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.

Country City Firm Name
India
Polepally, Mahaboob Nagar Aurobindo Pharma Limited
Sangareddy Aurobindo Pharma Limited
Bachupally Aurobindo Pharma Limited
Medchal Aurobindo Pharma Ltd
United States
East Windsor Aurobindo Pharma USA Inc





3. ENDO OPERATIONS

Endo Operations Ltd has filed for 1 generic for Dutasteride; Tamsulosin Hydrochloride. This 0.5mg;0.4mg version comes by the name DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Endo Operations.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.5MG; 0.4MG

capsule Prescription ORAL AB Feb 26, 2014





4. ZYDUS PHARMS

Zydus Pharmaceuticals Usa Inc has filed for 1 generic for Dutasteride; Tamsulosin Hydrochloride. This 0.5mg;0.4mg version comes by the name DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Zydus Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.5MG; 0.4MG

capsule Prescription ORAL AB May 24, 2018